Breast Cancer

Panelists discuss how to contextualize inavolisib within the broader landscape of PIK3CA inhibitors, noting its improved tolerability compared with alpelisib while emphasizing the need for individualized treatment selection based on disease burden and the emerging challenge of managing comutations like ESR1.

Panelists discuss how the INAVO120 trial’s secondary end point showing delayed time to chemotherapy from 12 to 36 months with the triplet combination provides compelling quality-of-life benefits for patients while acknowledging the challenges of determining optimal treatment sequencing after progression on this regimen.

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Katherine C. Ansley, MD, discusses the importance of the phase 3 INAVO120 trial in PIK3CA-mutated, hormone receptor–positive, HER2-negative breast cancer.

Panelists discuss how the INAVO120 trial's final overall survival analysis showing a 7-month median survival benefit (34 vs 27 months) with inavolisib plus palbociclib plus fulvestrant in PIK3CA-mutated endocrine resistant breast cancer represents promising but complex data, given the low crossover rates and potential need for first-line PIK3CA inhibitor use before patients progress to chemotherapy.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the clinical implications of the phase 2 RIGHT Choice trial.

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

Nagi S. El-Saghir, MD, FACP, FASCO, discusses ribociclib plus endocrine therapy in premenopausal HR-positive breast cancer by liver metastases status.

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

The European Medicines Agency's CHMP has recommended the use of denosumab biosimilars referencing Prolia and Xgeva in all reference product indications.

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.